Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Chief Financial Officer | September 02, 2026 | September 03, 2026 |
| bluebird bio, Inc.BLUE · Entity 78923 | Principal Accounting Officer | August 03, 2020 | August 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,277 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Tax withholding · Disposed 1,733 · Balance 117,277 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
bluebird bio, Inc.
Report date August 03, 2020 · Filed August 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,512 |
Reported balance
After 2020-08-03 transaction · row 1
1 source rowRow 1 · 2020-08-03 · Sale · Disposed 82 · Balance 9,512 F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 18, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 18, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 21, 2023 Filed Dec 26, 2023 21:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 2,200 | $2.10 | $4,620.00 |
DisclosureSEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. Read SEC document |
| September 06, 2023 Filed Sep 6, 2023 21:11 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 46 | $14.03 | $645.38 |
DisclosureSEC source: 0001689375-23-000064 · wf-form4_169403465097330.xml · nonDerivative · entry 4 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,571 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. Read SEC document |
| September 06, 2023 Filed Sep 6, 2023 21:11 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 904 | $13.45 | $12,160.79 |
DisclosureSEC source: 0001689375-23-000064 · wf-form4_169403465097330.xml · nonDerivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,617 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.01 to $14.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:11 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 426 | $14.46 | $6,161.03 |
DisclosureSEC source: 0001689375-23-000064 · wf-form4_169403465097330.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,521 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:11 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $15.41 | $0.00 |
DisclosureSEC source: 0001689375-23-000064 · wf-form4_169403465097330.xml · derivative · entry 5 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-09-01 F5 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:11 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 14,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000064 · wf-form4_169403465097330.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,947 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,884 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-23-000048 · wf-form4_168919407796459.xml · derivative · entry 6 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,657 Underlying: Common Stock · 3,884 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,884 | $18.00 | $69,903.84 |
DisclosureSEC source: 0001689375-23-000048 · wf-form4_168919407796459.xml · nonDerivative · entry 4 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,747 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.95 to $18.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 3,884 | $2.10 | $8,156.40 |
DisclosureSEC source: 0001689375-23-000048 · wf-form4_168919407796459.xml · nonDerivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,116 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-23-000048 · wf-form4_168919407796459.xml · derivative · entry 5 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,541 Underlying: Common Stock · 6,116 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 6,116 | $17.98 | $109,958.34 |
DisclosureSEC source: 0001689375-23-000048 · wf-form4_168919407796459.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,747 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.95 to $18.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 6,116 | $2.10 | $12,843.60 |
DisclosureSEC source: 0001689375-23-000048 · wf-form4_168919407796459.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,790 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-23-000045 · wf-form4_168815716514000.xml · derivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,657 Underlying: Common Stock · 8,790 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 8,790 | $2.10 | $18,459.00 |
DisclosureSEC source: 0001689375-23-000045 · wf-form4_168815716514000.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:20 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-23-000044 · wf-form4_168755161282030.xml · derivative · entry 4 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,447 Underlying: Common Stock · 17,500 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:20 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 8,907 | $15.17 | $135,128.99 |
DisclosureSEC source: 0001689375-23-000044 · wf-form4_168755161282030.xml · nonDerivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,957 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.05 to $15.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:20 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 8,593 | $14.84 | $127,519.26 |
DisclosureSEC source: 0001689375-23-000044 · wf-form4_168755161282030.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,864 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $15.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:20 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 17,500 | $2.10 | $36,750.00 |
DisclosureSEC source: 0001689375-23-000044 · wf-form4_168755161282030.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:37 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 145 | $11.23 | $1,628.09 |
DisclosureSEC source: 0001689375-23-000015 · wf-form4_167787941368609.xml · nonDerivative · entry 4 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,157 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.345, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:37 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,602 | $10.46 | $16,760.93 |
DisclosureSEC source: 0001689375-23-000015 · wf-form4_167787941368609.xml · nonDerivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,302 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.03 to $10.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:37 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,005 | $11.60 | $11,654.18 |
DisclosureSEC source: 0001689375-23-000015 · wf-form4_167787941368609.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,904 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:37 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001689375-23-000015 · wf-form4_167787941368609.xml · derivative · entry 5 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2033-03-01 F6 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:37 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 28,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000015 · wf-form4_167787941368609.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,909 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| March 01, 2023 Filed Apr 19, 2023 21:49 UTC Amendment | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001689375-23-000028 · wf-form4a_168194095268908.xml · derivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-03-01 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027. F2 · balance_after: The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively. Read SEC document |
| March 01, 2023 Filed Apr 19, 2023 21:49 UTC Amendment | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 14,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000028 · wf-form4a_168194095268908.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,957 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F2 · balance_after: The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,550 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000049 · wf-form4_167088097289071.xml · derivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,947 Underlying: Common Stock · 4,550 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 4,550 | $18.95 | $86,237.97 |
DisclosureSEC source: 0001689375-22-000049 · wf-form4_167088097289071.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,509 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.51 to $19.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 4,550 | $2.10 | $9,555.00 |
DisclosureSEC source: 0001689375-22-000049 · wf-form4_167088097289071.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 22:02 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000048 · wf-form4_167036411201797.xml · derivative · entry 6 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,497 Underlying: Common Stock · 200 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 22:02 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 200 | $18.05 | $3,610.00 |
DisclosureSEC source: 0001689375-22-000048 · wf-form4_167036411201797.xml · nonDerivative · entry 4 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,509 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 22:02 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 200 | $2.10 | $420.00 |
DisclosureSEC source: 0001689375-22-000048 · wf-form4_167036411201797.xml · nonDerivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 22:02 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,910 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000048 · wf-form4_167036411201797.xml · derivative · entry 5 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,697 Underlying: Common Stock · 2,910 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 22:02 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,910 | $18.20 | $52,949.49 |
DisclosureSEC source: 0001689375-22-000048 · wf-form4_167036411201797.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,509 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 22:02 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 2,910 | $2.10 | $6,111.00 |
DisclosureSEC source: 0001689375-22-000048 · wf-form4_167036411201797.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:59 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000046 · wf-form4_166880877585675.xml · derivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,607 Underlying: Common Stock · 200 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:59 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 200 | $18.10 | $3,620.00 |
DisclosureSEC source: 0001689375-22-000046 · wf-form4_166880877585675.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,509 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:59 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 200 | $2.10 | $420.00 |
DisclosureSEC source: 0001689375-22-000046 · wf-form4_166880877585675.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · balance_after: The Form 4 filed by the reporting person on August 18, 2022 inadvertently understated the number of common shares owned following the transactions reported therein by 20 shares, an error that was carried forward onto the reporting person's subsequent Form 4 filings. Immediately prior to the transactions reported herein, the correct number of shares of common stock owned by the reporting person was 16,509 shares. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 5,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-097878 · tm2225276-1_4seq1.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,489 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 20:06 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,551 | $14.18 | $21,986.05 |
DisclosureSEC source: 0001104659-22-095126 · tm2224609-1_4seq1.xml · nonDerivative · entry 4 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,986 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.74 to $14.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:06 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,117 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001104659-22-095126 · tm2224609-1_4seq1.xml · derivative · entry 5 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,807 Underlying: Common Stock · 1,117 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F5 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:06 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 301 | $14.23 | $4,282.33 |
DisclosureSEC source: 0001104659-22-095126 · tm2224609-1_4seq1.xml · nonDerivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,537 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.17 to $14.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:06 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,817 | $13.52 | $38,093.16 |
DisclosureSEC source: 0001104659-22-095126 · tm2224609-1_4seq1.xml · nonDerivative · entry 2 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,838 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.06 to $13.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 20:06 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 1,117 | $2.10 | $2,345.70 |
DisclosureSEC source: 0001104659-22-095126 · tm2224609-1_4seq1.xml · nonDerivative · entry 1 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| August 23, 2022 Filed Aug 23, 2022 22:28 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,403 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001104659-22-093784 · tm2224405-1_4seq1.xml · derivative · entry 9 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,924 Underlying: Common Stock · 1,403 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F5 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 23, 2022 Filed Aug 23, 2022 22:28 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,909 | $13.09 | $38,079.68 |
DisclosureSEC source: 0001104659-22-093784 · tm2224405-1_4seq1.xml · nonDerivative · entry 6 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,538 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2022 Filed Aug 23, 2022 22:28 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 1,403 | $2.10 | $2,946.30 |
DisclosureSEC source: 0001104659-22-093784 · tm2224405-1_4seq1.xml · nonDerivative · entry 5 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 22:28 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 117 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001104659-22-093784 · tm2224405-1_4seq1.xml · derivative · entry 8 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,327 Underlying: Common Stock · 117 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F5 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 22:28 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 217 | $13.00 | $2,822.02 |
DisclosureSEC source: 0001104659-22-093784 · tm2224405-1_4seq1.xml · nonDerivative · entry 4 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,044 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 22:28 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 117 | $2.10 | $245.70 |
DisclosureSEC source: 0001104659-22-093784 · tm2224405-1_4seq1.xml · nonDerivative · entry 3 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 22:28 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,452 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001104659-22-093784 · tm2224405-1_4seq1.xml · derivative · entry 7 WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,444 Underlying: Common Stock · 4,452 shares Expires 2030-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F5 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.